<DOC>
	<DOC>NCT00269516</DOC>
	<brief_summary>This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.</brief_summary>
	<brief_title>SLV308 for Treatment of Patients With Early Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Diagnosis of idiopathic Parkinson's Disease, Early stage of disease, Modified Hoehn &amp; Yahr up to stage III, UPDRS motor score (part III) 10 at baseline. Diagnosis is unclear or a suspicion of other parkinsonian syndromes, Patients who have undergone surgery for the treatment of PD, Presence of dyskinesias, Motor fluctuations or loss of postural reflexes, Clinically significant abnormalities, Patients treated with Ldopa or dopamine agonists currently or in the past (for more than 3 months in total), Antipsychotic.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Parkinson's disease</keyword>
</DOC>